近十年SCI著作

　　1. Guo S, Wang B, Fu L, Chen X, Zhang W, Huang H, Lu Y. In vitro and in vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2021 Aug 16:AAC0097421.

　　2. Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2021. 65(4):e02418-20.

　　3. Li P, Wang B, Fu L, Guo K, Ma C, Wang B, Lin Z, Li G, Huang H, Lu Y. Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis. Eur J Med Chem. 2021 Oct 15;222:113603.

　　4. Wang A, Xu S, Chai Y, Xia G, Wang B, Lv K, Ma C, Wang D, Wang A, Qin X, Liu M, Lu Y. Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis. Eur J Med Chem. 2021 Jun 5;218:113398.

　　5. Zhu H, Fu L, Wang B, Chen X, Zhao J, Huang H, Lu Y. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02164-20.

　　6. Chen H, Wang B, Li P, Yan H, Li G, Huang H, Lu Y. The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition. Bioorg Med Chem Lett. 2021 May 15;40:127924.

　　7. Guo S, Fu L, Wang B, Chen X, Zhao J, Liu M, Lu Y. In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis. Biomed Pharmacother. 2020 Nov;131:110777.

　　8. Xi AQ, Zhuo M, Dai JT, Ding YH, Ma XZ, Ma XL, Wang XY, Shi LM, Bai HY, Zheng HY, Nuermberger E, Xu J*(通讯作者). Epidemiological and Clinical Characteristics of Discharged Patients Infected With SARS-CoV-2 on the Qinghai Plateau. J Med Virol, 2020; 92(11):2528-2535. doi: 10.1002/jmv.26032.

　　9. Zhao H, Wang B, Fu L, Li G, Lu H, Liu Y, Sheng L, Li Y, Zhang B, Lu Y, Ma C, Huang H, Zhang D, Lu Y. Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis. J Med Chem. 2020 Sep 10;63(17):9316-9339.

　　10. Wang A, Lu Y, Lv K, Ma C, Xu S, Wang B, Wang A, Xia G, Liu M. Design, synthesis and antimycobacterial activity of new benzothiazinones inspired by rifampicin/rifapentine. Bioorg Chem. 2020 Sep;102:104135.

　　11. Li P, Wang B, Li G, Fu L, Zhang D, Lin Z, Huang H, Lu Y. Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis. Eur J Med Chem. 2020 Nov 15;206:112538.

　　12. Liu P, Fan S, Wang B, Cao R, Wang X, Li S, Lu Y, Zhong W. Design, synthesis and biological evaluation of novel triaryldimethylaminobutan-2-ol derivatives against Mycobacterium tuberculosis. Bioorg Chem. 2020 Sep;102:104054.

　　13. Wang A, Ma C, Chai Y, Liu X, Lv K, Fu L, Wang B, Jia X, Liu M, Lu Y. Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents. Eur J Med Chem. 2020 Aug 15;200:112409.

　　14. Zhao W, Wang B, Liu Y, Fu L, Sheng L, Zhao H, Lu Y, Zhang D. Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis. Eur J Med Chem. 2020 Mar 1;189:112075.

　　15. Hu M, Fu L, Wang B, Xu J, Guo S, Zhao J, Li Y, Chen X, Lu Y. Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro. Infect Drug Resist. 2020 Jun 12;13:1751-1761.

　　16. Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother. 2019;63(5):e00021-19.

　　17. Wang A, Lv K, Tao Z, Gu J, Fu L, Liu M, Wan B, Franzblau SG, Ma C, Ma X, Han B, Wang A, Xu S, Lu Y. Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. Eur J Med Chem. 2019 Nov 1;181:111595.

　　18. Zhang Y, Zhu H, Fu L, Wang B, Guo S, Chen X, Liu Z, Huang H, Yang T, Lu Y. Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e02496-18.

　　19. Lv K, Wang A, Tao Z, Fu L, Liu H, Wang B, Ma C, Wang H, Ma X, Han B, Wang A, Zhang K, Liu M, Lu Y. hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents. Eur J Med Chem. 2019 Oct 1;179:208-217.

　　20. Wang A, Lv K, Li L, Liu H, Tao Z, Wang B, Liu M, Ma C, Ma X, Han B, Wang A, Lu Y. Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents. Eur J Med Chem. 2019 Sep 15;178:715-725.

　　21. Xu J, Wang B, Fu L, Zhu H, Guo S, Huang H, Yin D, Zhang Y, Lu Y. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02155-18.

　　22. Wang A, Wang H, Geng Y, Fu L, Gu J, Wang B, Lv K, Liu M, Tao Z, Ma C, Lu Y. Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties. Bioorg Med Chem. 2019 Mar 1;27(5):813-821.

　　23. Ren J, Xu J, Zhang G, Xu C, Zhao L, You X, Wang Y, Lu Y, Yu L, Wang J. Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents. Bioorg Med Chem Lett. 2019 Feb 15;29(4):539-543.

　　24. Zhang D, Lin Y, Chen X, Zhao W, Chen D, Gao M, Wang Q, Wang B, Huang H, Lu Y, Lu Y. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold. Bioorg Chem. 2019 Apr;85:229-239.

　　25. Wang H, Wang A, Gu J, Fu L, Lv K, Ma C, Tao Z, Wang B, Liu M, Guo H, Lu Y. Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives. Eur J Med Chem. 2019 Mar 1;165:11-17.

　　26. H Zhu, S-C Guo, Z-Q Liu, B Wang, L Fu, N-H Chu, Y Lu. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):931-936.

　　27. Li P, Wang B, Zhang X, Batt SM, Besra GS, Zhang T, Ma C, Zhang D, Lin Z, Li G, Huang H, Lu Y. Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones. Eur J Med Chem. 2018 Dec 5;160:157-170.

　　28. Wang A, Li W, Wang B, Lv K, Wang H, Liu M, Guo H, Lu Y. Synthesis and evaluation of nitrofuranyl methyl N-heterocycles derivatives as novel antitubercular agents. Future Med Chem. 2018 Sep 1;10(17):2059-2068.

　　29. Wang A, Huang G, Wang B, Lv K, Wang H, Tao Z, Liu M, Guo H, Lu Y. Design, synthesis and antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties. Bioorg Med Chem Lett. 2018 Sep 15;28(17):2945-2948.

　　30. Zhang Y, Zhu H, Yang X, Guo S, Liang Q, Lu Y, Chen X. Serum vitamin D level and vitamin D receptor genotypes may be associated with tuberculosis clinical characteristics: A case-control study. Medicine (Baltimore). 2018 Jul;97(30):e11732.

　　31. Li L, Lv K, Yang Y, Sun J, Tao Z, Wang A, Wang B, Wang H, Geng Y, Liu M, Guo H, Lu Y. Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents. ACS Med Chem Lett. 2018 Jun 26;9(7):741-745.

　　32. Lv K, Tao Z, Liu Q, Yang L, Wang B, Wu S, Wang A, Huang M, Liu M, Lu Y. Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. Eur J Med Chem. 2018 May 10;151:1-8.

　　33. Wang A, Yang Y, Jun Y, Wang B, Lv K, Liu M, Guo H, Lu Y. Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents. Bioorg Med Chem. 2018 May 1;26(8):2073-2084.

　　34. Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01692-17.

　　35. Li L, Jin Y, Wang B, Yang Z, Liu M, Guo H, Zhang J, Lu Y. A structure-based strategy toward the development of novel candidates for antimycobacterial activity: Synthesis, biological evaluation, and docking study. Chem Biol Drug Des. 2018 Mar;91(3):769-780.

　　36. Xu J, Wang JX, Zhou JM, Xu CL, Huang B, Xing Y, Wang B, Luo R, Wang YC, You XF, Lu Y, Yu LY. A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity. Sci Rep. 2017 Jul 11;7(1):5093.

　　37. Lv K, Li L, Wang B, Liu M, Wang B, Shen W, Guo H, Lu Y. Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives. Eur J Med Chem. 2017 Sep 8;137:117-125.

　　38. Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, Nuermberger E, Lu Y. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017 May 24;61(6):e00239-17.

　　39. Lv K, You X, Wang B, Wei Z, Chai Y, Wang B, Wang A, Huang G, Liu M, Lu Y. Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents. ACS Med Chem Lett. 2017 May 10;8(6):636-641.

　　40. Zhao H, Lu Y, Sheng L, Yuan Z, Wang B, Wang W, Li Y, Ma C, Wang X, Zhang D, Huang H. Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis. ACS Med Chem Lett. 2017 Apr 12;8(5):533-537.

　　41. Wu Z, Lu Y, Li L, Zhao R, Wang B, Lv K, Liu M, You X. Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents. ACS Med Chem Lett. 2016 Oct 11;7(12):1130-1133.

　　42. Huang J, Wang M, Wang B, Wu Z, Liu M, Feng L, Zhang J, Li X, Yang Y, Lu Y. Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety. Bioorg Med Chem Lett. 2016 May 1;26(9):2262-7.

　　43. Li L, Li Z, Liu M, Shen W, Wang B, Guo H, Lu Y. Design, Synthesis and Antimycobacterial Activity of Novel Imidazo[1,2-a]pyridine Amide-Cinnamamide Hybrids. Molecules. 2015 Dec 30;21(1):E49.

　　44. Huang J, Liu H, Liu M, Zhang R, Li L, Wang B, Wang M, Wang C, Lu Y. Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5058-63.

　　45. Zhang T, Shen W, Liu M, Zhang R, Wang M, Li L, Wang B, Guo H, Lu Y. Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety. Eur J Med Chem. 2015 Nov 2;104:73-85.

　　46. Zhu H, Guo SC, Hao LH, Liu CC, Wang B, Fu L, Chen MT, Zhou L, Chi JY, Yang W, Nie WJ, Lu Y. Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations. Chin Med J (Engl). 2015 Feb 20;128(4):433-7.

　　47. Nie W, Duan H, Huang H, Lu Y, Chu N. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. Biomed Res Int. 2015;2015:506598.

　　48. Liu H, Huang J, Wang J, Wang M, Liu M, Wang B, Guo H, Lu Y. Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety. Eur J Med Chem. 2014 Oct 30;86:628-38.

　　49. Zhang D, Liu Y, Zhang C, Zhang H, Wang B, Xu J, Fu L, Yin D, Cooper CB, Ma Z, Lu Y, Huang H. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules. 2014 Apr 9;19(4):4380-94.

　　50. Zheng M, Jin H, Fu L, Xu J, Wang B, Zhao W, Zhu H, Li P, Lu Y, Li Q. A comparative study on the activities of six combination regimens against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. J Chemother. 2013 Apr;25(2):81-6.

　　51. Wei Z, Wang J, Liu M, Li S, Sun L, Guo H, Wang B, Lu Y. Synthesis, in vitro antimycobacterial and antibacterial evaluation of IMB-070593 derivatives containing a substituted benzyloxime moiety. Molecules. 2013 Mar 28;18(4):3872-93.

　　52. Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. Clin Ther. 2013 Feb;35(2):161-8.

　　53. Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong N, Lv Y, Li C, Cooper CB, Upton AM, Yin D, Ma Z, Huang H. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem. 2012 Oct 11;55(19):8409-17.

　　54. Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis. 2012;16(8):1119-25.

　　55. Wang S, Jia XD, Liu ML, Lu Y, Guo HY. Synthesis, antimycobacterial and antibacterial activity of ciprofloxacin derivatives containing a N-substituted benzyl moiety. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5971-5.

　　56. Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D, Huang H, Upton AM, Ma Z. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother. 2011 Nov;55(11):5185-93.